The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing, China.
Department of Clinical Laboratory, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Biomed Res Int. 2020 Mar 3;2020:1839205. doi: 10.1155/2020/1839205. eCollection 2020.
Breast invasive carcinoma (BRCA) is the most common malignant tumor. MiR-124 plays a tumor-suppressive role in human cancer. However, the clinical significance of miR-124 in BRCA remains unclear. The aim of this study was to evaluate the association of hsa-mir-124 expression and the clinicopathological characteristics in BRCA using database analysis.
The clinical data and expression profiles of hsa-mir-124 were obtained from the cancer genome atlas for BRCA (TCGA_BRCA). Then, the prognostic value of hsa-mir-124 in BRCA was investigated using the Cox Regression test, and the association of hsa-mir-124 and pathology TNM stages and pathologic stages were measured by the Kruskal-Wallis test and Wilcox. test. In addition, the association of hsa-mir-124 and tumor molecular phenotypes was performed using the Chi-Square test.
We found that the overall survival of patients with high expression of hsa-mir-124-1 and hsa-mir-124-2 was better than that of patients with low expression of hsa-mir-124-1 and hsa-mir-124-2. And the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was mainly enriched in T1/T2 stages, NO/N1 stages, and M0 stages. Then, the expression of hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-3 was negatively associated with tumor lymph node metastasis. Moreover, the expression of hsa-mir-124 was associated with tumor molecular phenotype in breast invasive carcinoma.
Our findings indicated that hsa-mir-124 expressions were associated with overall survival, TNM stages, pathologic characteristics, and tumor molecular phenotype in BRCA via TCGA_BRCA database, providing a new biomarker and a potential therapeutic target for BRCA patients.
乳腺浸润性癌（BRCA）是最常见的恶性肿瘤。miR-124 在人类癌症中发挥着肿瘤抑制作用。然而，miR-124 在 BRCA 中的临床意义尚不清楚。本研究旨在通过数据库分析评估 hsa-mir-124 的表达与 BRCA 临床病理特征的相关性。
从癌症基因组图谱（TCGA_BRCA）中获取 hsa-mir-124 的临床数据和表达谱。然后，使用 Cox 回归检验研究 hsa-mir-124 在 BRCA 中的预后价值，并通过 Kruskal-Wallis 检验和 Wilcox 检验测量 hsa-mir-124 与病理 TNM 分期和病理分期的关系。此外，使用卡方检验研究 hsa-mir-124 与肿瘤分子表型的关系。
我们发现 hsa-mir-124-1 和 hsa-mir-124-2 高表达患者的总生存率优于 hsa-mir-124-1 和 hsa-mir-124-2 低表达患者。hsa-mir-124-1、hsa-mir-124-2 和 hsa-mir-124-3 的表达主要富集在 T1/T2 期、NO/N1 期和 M0 期。然后，hsa-mir-124-1、hsa-mir-124-2 和 hsa-mir-124-3 的表达与肿瘤淋巴结转移呈负相关。此外，hsa-mir-124 的表达与乳腺浸润性癌的肿瘤分子表型相关。
通过 TCGA_BRCA 数据库，我们的研究结果表明，hsa-mir-124 的表达与 BRCA 的总生存率、TNM 分期、病理特征和肿瘤分子表型相关，为 BRCA 患者提供了新的生物标志物和潜在的治疗靶点。
